Matassa, V.G. et al, J. Med. Chem., v. 33, 1781 (1990);
U. S. Patent No. 4,859,692;
U. S. Patent No. 5,993,859;
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily.